251
Phase I/II Study of SLAMF7 FPBMC/CS-1 FPBMC in Relapsed/Refractory Multiple Myeloma
Condition(s):Multiple MyelomaLast Updated:May 9, 2023Recruiting
Refractory Multiple Myeloma: 1469 Clinical Trials, Page 26 of 147
Hide Studies Not Open or Pending
252
Filgrastim in Treating Patients With Bortezomib-, Carfilzomib-, or IMID-Refractory Multiple Myeloma
Condition(s):Multiple MyelomaLast Updated:January 26, 2015Terminated
253
Safety and Efficacy Study of OPC-415 in Patients With Relapsed and/or Refractory Multiple Myeloma
Condition(s):Multiple Myeloma (MM)Last Updated:April 22, 2022Recruiting
254
Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma
Condition(s):Recurrent Plasma Cell Myeloma; Refractory Plasma Cell MyelomaLast Updated:February 3, 2023Recruiting
255
A Phase 1/2 Study of a Fully Human BCMA-targeting CAR (CT103A) in Patients With Relapsed/Refractory Multiple Myeloma (FUMANBA-1)
Condition(s):Multiple MyelomaLast Updated:November 23, 2021Recruiting
256
A Study of C-CAR088 in Patients With Relapsed or Refractory Multiple Myeloma
Condition(s):Multiple MyelomaLast Updated:March 24, 2023Recruiting
257
A Safety and Efficacy Study Evaluating CTX120 in Subjects With Relapsed or Refractory Multiple Myeloma
Condition(s):Multiple MyelomaLast Updated:July 18, 2022Active, not recruiting
258
PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma
Condition(s):Multiple MyelomaLast Updated:May 22, 2023Recruiting
259
Safety and Efficacy of Anti-BCMA/GPRC5D CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma(rr/MM)
Condition(s):Multiple MyelomaLast Updated:August 22, 2022Recruiting
260
A Study of CAR-T Cells Targeting Both BCMA and GPRC5D in Treatment of Relapsed or Refractory Multiple Myeloma
Condition(s):Multiple MyelomaLast Updated:April 13, 2022Not yet recruiting